Insys Shareholders Ink Deal With Ex-CEO Over Fraud Claims
Law360 (July 14, 2020, 10:32 PM EDT) -- A proposed shareholder class announced a settlement with Insys Therapeutics' former CEO in Arizona federal court Tuesday, which would resolve securities fraud claims over the company's alleged kickbacks to doctors who prescribed an addictive opioid spray.
Although the terms of the deal weren't disclosed, lead plaintiff Clark Miller said the proposed class and former Insys CEO Michael Babich have agreed to resolve allegations against Babich for his purported role in the alleged bribery, according to a brief notice. The parties indicated that they are in the process of drafting a motion for preliminary approval and said it should be ready to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!